William Blair analyst Lachlan Hanbury Brown has maintained their bullish stance on APLS stock, giving a Buy rating today.
Lachlan Hanbury Brown has given his Buy rating due to a combination of factors surrounding Apellis Pharmaceuticals’ recent performance and strategic positioning. The company’s fourth-quarter earnings were strong, with revenues aligning closely with expectations and a narrower net loss than anticipated, primarily due to reduced R&D and SG&A expenses. Syfovre, a key product, has shown robust demand, maintaining a market share of over 60% and increasing new patient share to nearly 50%.
Management’s strategic initiatives, such as leveraging the differentiated profile of Syfovre through updated labels and real-world data presentations, have further solidified its market position. Additionally, Apellis is actively engaging in direct-to-consumer marketing campaigns and working with payers to secure favorable positioning, which is expected to yield benefits in the future. These factors collectively underpin the confidence in Apellis’s growth prospects, justifying the Buy rating.
In another report released today, TD Cowen also maintained a Buy rating on the stock with a $60.00 price target.